The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Can KRd + HSCT overcome the poor prognosis of harboring a high-risk cytogenetic aberration?
Featured:
Roberto MinaVideo series
During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Roberto Mina, University of Turin, Turin, IT. We asked, Can carfilzomib, lenalidomide, and dexamethasone (KRd) + hematopoietic stem cell transplantation overcome the poor prognosis of harboring a high-risk cytogenetic aberration?
In this video, Mina discusses the results of a subgroup analysis of the FORTE study (NCT02203643) evaluating the efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (KCd) or lenalidomide and dexamethasone (KRd) with or without transplant.
More from this series:
